Literature DB >> 9696838

Measles virus spread and pathogenesis in genetically modified mice.

B Mrkic1, J Pavlovic, T Rülicke, P Volpe, C J Buchholz, D Hourcade, J P Atkinson, A Aguzzi, R Cattaneo.   

Abstract

Attenuated Edmonston measles virus (MV-Edm) is not pathogenic in standard mice. We show here that MV-Edm inoculated via the natural respiratory route has a limited propagation in the lungs of mice with a targeted mutation inactivating the alpha/beta interferon receptor. A high dose of MV-Edm administered intracerebrally is lethal for about half of these mice. To study the consequences of the availability of a high-affinity receptor for MV propagation, we generated alpha/beta interferon-defective mice expressing human CD46 with human-like tissue specificity. Intranasal infection of these mice with MV-Edm resulted in enhanced spread to the lungs and more prominent inflammatory response. Virus replication was also detected in peripheral blood mononuclear cells, the spleen, and the liver. Moreover, intracerebral inoculation of adult animals with low MV-Edm doses caused encephalitis with almost inevitably lethal outcome. We conclude that in mice alpha/beta interferon controls MV infection and that a high-affinity receptor facilitates, but is not strictly required for, MV spread and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696838      PMCID: PMC109970     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains.

Authors:  V Lecouturier; J Fayolle; M Caballero; J Carabaña; M L Celma; R Fernandez-Muñoz; T F Wild; R Buckland
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

2.  Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells.

Authors:  H Schneider; K Kaelin; M A Billeter
Journal:  Virology       Date:  1997-01-20       Impact factor: 3.616

Review 3.  Subacute sclerosing panencephalitis.

Authors:  G G Gascon
Journal:  Semin Pediatr Neurol       Date:  1996-12       Impact factor: 1.636

4.  Generation of transgenic mice with yeast artificial chromosomes.

Authors:  L Montoliu; A Schedl; G Kelsey; P Lichter; Z Larin; H Lehrach; G Schütz
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1993

5.  Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro.

Authors:  J Schlender; J J Schnorr; P Spielhoffer; T Cathomen; R Cattaneo; M A Billeter; V ter Meulen; S Schneider-Schaulies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Mechanism of suppression of cell-mediated immunity by measles virus.

Authors:  C L Karp; M Wysocka; L M Wahl; J M Ahearn; P J Cuomo; B Sherry; G Trinchieri; D E Griffin
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

7.  Antigenic determinants of measles virus hemagglutinin associated with neurovirulence.

Authors:  U G Liebert; S G Flanagan; S Löffler; K Baczko; V ter Meulen; B K Rima
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Characterization of the promoter region of the membrane cofactor protein (CD46) gene of the human complement system and comparison to a membrane cofactor protein-like genetic element.

Authors:  W Cui; D Hourcade; T Post; A C Greenlund; J P Atkinson; V Kumar
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

9.  Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections.

Authors:  B Horvat; P Rivailler; G Varior-Krishnan; A Cardoso; D Gerlier; C Rabourdin-Combe
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  145 in total

Review 1.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

2.  In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein.

Authors:  W P Duprex; S McQuaid; B Roscic-Mrkic; R Cattaneo; C McCallister; B K Rima
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Recombinant measles viruses efficiently entering cells through targeted receptors.

Authors:  U Schneider; F Bullough; S Vongpunsawad; S J Russell; R Cattaneo
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.

Authors:  Sompong Vongpunsawad; Numan Oezgun; Werner Braun; Roberto Cattaneo
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.

Authors:  Aditi Dey; Yu Zhang; Anna Z Castleton; Katharine Bailey; Brendan Beaton; Bella Patel; Adele K Fielding
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

6.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

7.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Authors:  Marlyse C Knuchel; René R Marty; Teldja Neige Azzouz Morin; Orhan Ilter; Armando Zuniga; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

9.  An immune competent mouse model for the characterization of recombinant measles vaccines.

Authors:  René R Marty; Marlyse C Knuchel; Teldja Neige Azzouz Morin; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.